A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults
| dc.contributor.author | Newman, M.J. | |
| dc.contributor.author | Jin, X. | |
| dc.contributor.author | De-Rosa, S. | |
| dc.contributor.author | Cooper, C. | |
| dc.contributor.author | Thomas, E. | |
| dc.contributor.author | Keefer, M. | |
| dc.contributor.author | Fuchs, J. | |
| dc.contributor.author | Blattner, W. | |
| dc.contributor.author | Livingston, B.D. | |
| dc.contributor.author | McKinney, D.M. | |
| dc.contributor.author | Noonan, E. | |
| dc.contributor.author | Decamp, A. | |
| dc.contributor.author | Defawe, O.D. | |
| dc.contributor.author | Wecker, M. | |
| dc.date.accessioned | 2012-05-17T15:40:37Z | |
| dc.date.accessioned | 2017-10-19T12:11:00Z | |
| dc.date.available | 2012-05-17T15:40:37Z | |
| dc.date.available | 2017-10-19T12:11:00Z | |
| dc.date.issued | 2009 | |
| dc.description.abstract | A Phase I human vaccine trial of a novel polypeptide vaccine of HIV T helper epitopes (EP-1043) and a DNA vaccine of HIV CTL epitopes was conducted in 84 healthy adult volunteers. The vaccine immunogenicity was assessed by an intracellular cytokine staining assay for IL-2, IL-4, TNF-alpha and IFN-gamma. Sixty eight percent (32/47) of subjects had a positive CD4+ T response after receiving two vaccinations of the polypeptide vaccine. The responding CD4+ T cells made various combinations of IL-2, IL-4, IFN-gamma, and TNF-alpha. The study demonstrated that the EP-1043 vaccine is safe, well-tolerated, and immunogenic. | en_US |
| dc.identifier.citation | Vaccine Journal. 27(50): 7080-6 | en_US |
| dc.identifier.uri | http://197.255.68.203/handle/123456789/1484 | |
| dc.language.iso | en | en_US |
| dc.publisher | Vaccine Journal | en_US |
| dc.title | A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults | en_US |
| dc.type | Article | en_US |